MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaa016

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020

Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.

Pullen Matthew F, Hullsiek Katherine Huppler, Rhein Joshua, Musubire Abdu K, Tugume Lillian, Nuwagira Edwin, Abassi Mahsa, Ssebambulidde Kenneth, Mpoza Edward, Kiggundu Ruben, Akampurira Andrew, Nabeta Henry W, Schutz Charlotte, Evans Emily E, Rajasingham Radha, Skipper Caleb P, Pastick Katelyn A, Williams Darlisha A, Morawski Bozena M, Bangdiwala Ananta S, Meintjes Graeme, Muzoora Conrad, Meya David B, Boulware David R

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint for all-cause mortality. The Food and Drug Administration allows for using surrogate endpoints for accelerated regulatory approval, but EFA as a surrogate endpoint requires further validation. We examined the relationship between rate of CSF Cryptococcus clearance (EFA) and mortality through 18 weeks.

METHODS

We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during 2010-2017. All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitative CSF cultures. The log10-transformed colony-forming units (CFUs) per mL CSF were analyzed by general linear regression versus day of culture over the first 10 days.

RESULTS

Mortality through 18 weeks was 37% for EFA > = 0.60 (n = 170), 36% for 0.40-0.59 (n = 182), 39% for 0.30-0.39 (n = 112), 35% for 0.20-0.29 (n = 87), and 50% for those with EFA < 0.20 CFU/mL/day (n = 187). The hazard ratio for 18-week mortality, comparing those with EFA < 0.20 to those with EFA > = 0.20, was 1.60 (95% confidence interval, 1.25, 2.04; P = .002). The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients with CSF pleocytosis (P < .001).

CONCLUSIONS

EFA is associated with all-cause mortality in cryptococcal meningitis. An EFA threshold of > = 0.20 log10 CFU/mL/day was associated with similar 18-week mortality (37%) compared to 50% mortality with EFA < 0.20. This EFA threshold may be considered a target for a surrogate endpoint. This builds upon existing studies to validate EFA as a surrogate endpoint.

Для цитирования: Pullen Matthew F, Hullsiek Katherine Huppler, Rhein Joshua, Musubire Abdu K, Tugume Lillian, Nuwagira Edwin, Abassi Mahsa, Ssebambulidde Kenneth, Mpoza Edward, Kiggundu Ruben, Akampurira Andrew, Nabeta Henry W, Schutz Charlotte, Evans Emily E, Rajasingham Radha, Skipper Caleb P, Pastick Katelyn A, Williams Darlisha A, Morawski Bozena M, Bangdiwala Ananta S, Meintjes Graeme, Muzoora Conrad, Meya David B, Boulware David R. Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. DOI: 10.1093/cid/ciaa016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.